Jianshi Technology announced on the Hong Kong Stock Exchange that since the company received notification from the National Drug Administration Evaluation Center on March 25, 2024 that LUX-Valve's technical evaluation at the registration technology review stage was not passed, the State Drug Administration announced that it had not passed the LUX-Valve registration application on April 24. The company will continue to evaluate the impact of the National Drug Administration's decision and promote the global commercialization process of the LUX-Valve series products. At the same time, the company will make careful and timely management adjustments to ensure the smooth development and long-term sustainable development of the company's business.
健世科技：LuX-Valve注册申请未获国家药监局通过
Jianshi Technology: LUX-Valve registration application was not approved by the State Drug Administration
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.